The use of hirudin as universal anticoagulant in haematology, clinical chemistry and blood grouping.
Menssen HD, Melber K, Brandt N, Thiel E
Purpose
Conclusion
Studies (1)
Purpose
The purpose of this study was to evaluate hirudin as an anticoagulant and to assess potential alterations in routine clinical and hematological analytes.
Summary of Findings
Hirudin and K2EDTA treated blood specimens differed in leukocyte and thrombocyte counts by 4-7%, although the authors noted that differences were clinically irrelevant. All other blood cell and hemoglobin measurements were similar among hirudin and K2EDTA treated specimens. Hirudinized blood produced equivalent results to case-matched native blood specimens with respect to immunohematological testing. Of the 24 clinical analytes measured, 13 differed significantly among hirudin plasma and serum specimens, although only potassium, phosphate, lipase, and bilirubin differed by 5% or more.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
None (Fresh)Diagnoses
NormalNeoplasticLeukemiaDiabetes Type 2Other diagnosesPlatforms
Cell count/volumeCoulter counterProteinClinical chemistry/auto analyzerLipidClinical chemistry/auto analyzerSmall moleculeClinical chemistry/auto analyzerSteroidClinical chemistry/auto analyzerCarbohydrateClinical chemistry/auto analyzerElectrolyte/MetalClinical chemistry/auto analyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Anticoagulant HirudinPotassium EDTABiospecimen Aliquots and Components Blood and blood products PlasmaSerum